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Diabetes is a health condition characterized by a high level of blood glucose caused by a lack 
of insulin in the patient’s body. It is estimated that 1 in 11 adults in the world have diabetes and 
this number will increase rapidly over the next years, passing 600 million people in 2040,  
(Diabetes Community UK, 2019). The condition can be treated in different forms, and this 
factor has suffered a major change since the discovery of the disease, from patients doing 
starvation dieting in 20th century to the launch of an artificial pancreas in 2016, (American 
Diabetes Association, 2020.b).  
Diabetes is considered one of the most expensive health conditions of the world, the 
International Diabetes Federation (2019) estimates that around 10% of the global health 
expenditure is used by governments only in diabetes care, not considering the private 
investment that patients need to make to acquire necessary supplies. Along with that, 80% of 
patients come from middle and low income countries, where the socioeconomic, educational 
and healthcare contexts are less developed in comparison with higher income regions. 
Therefore, because the disease requires such high financial spending, there is a major problem 
of treatment accessibility and inequality around the world.  
When considering innovative options as a part of the treatment, the inequality gap is even 
bigger, as they are more expensive than traditional means, (Lansdown, 2017). Fortunately, it is 
known that technology plays a major role in developing diabetes treatment and giving patients 
much more freedom nowadays, providing good results and even compensating the financial 
investment in the long term, thus, there is a great effort to improve accessibility in different 
contexts, (International Diabetes Federation, 2019).  
Accordingly, to have a better understanding of the diabetes and technology topic, this work 
project explores four factors that limit the percentage of patients with access to diabetes 
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technology worldwide. The objective is to explore the factors and understand how they restrict 
the adoption of such advanced treatments. In order to develop this research, it  was used a 
qualitative approach to analyze documents already available from governmental institutions, 
healthcare experts, diabetes associations from different countries, pharmaceutical companies 
and papers developed on diverse diabetes topics. 
The work project sections are divided as follows: (1) introduction, (2) background and 
definitions about diabetes and technology, (3) methodology used in the development of the 
research, (4) analysis of the factors that create a barrier to technology adoption, and finally (5) 
conclusion with the author’s discussion about the topic, followed by limitations and further 
work recommendations.  
2. Background and definitions 
2.1. Diabetes mellitus  
According to the World Health Organization (2016.b), diabetes mellitus occurs either when the 
pancreas do not produce enough insulin or the body do not make the right use of it, therefore, 
blood glucose cannot be controlled. The medical condition can be divided mainly by four 
different types, (i) gestational diabetes, when the woman develops the disease during the 
pregnancy only, (ii) Moody, when the patient secrets insulin until its pancreas stops working, 
and the most common ones (iii) type 1 and (iv) type 2. For the purpose of this research, the 
paper will be focused on the last two.   
The World Health Organization (2016.b) explains that patients with diabetes type 1 (T1) have 
a deficiency of insulin production in their body, leading to a dependence on the hormone to 
survive as part of their treatment. T1 counts for almost 10% of the cases, the disease is not 
preventable and the cause is not well established. On the other side, diabetes type 2 (T2) is 
characterized by the body’s inefficient use of insulin, most of the patients do not depend on it 
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to survive, needing a combination of different treatments to deal with the disease. T2 is 
responsible for almost 90% of the cases, being caused mainly by a long term unhealthy life 
style and genetic conditions.  
Regarding the total number of patients, there are approximately 470 million adults and more 
than 1.1 million kids and teenagers with diabetes around the world. The number of diabetics 
have tripled during the last 20 years and will exponentially grow over the next decades, 
especially in T2 cases, (International Diabetes Federation, 2019). The exhibit 1 pictures the 
prevalence of adult patients nowadays.  
Moreover, the condition is responsible for a big slice of health expenses in most of the countries. 
It is estimated that governments spend USD 760.3 billions and that this number increases in 
USD 90 billions over the next 10 years. China, India and the United States are the countries 
with the biggest number of patients (exhibit 2) and also higher total expenses in diabetes, around 
18% of the total annual health budget each, being 43% of the world diabetes expenses spent 
only in the North American and Caribbean region (International Diabetes Federation, 2019).   
Regarding the prevalence in specific regions, the fact that middle and low income countries 
have a higher incidence in comparison with high income countries can be explained by number 
of the population and lack of measurements to prevent diabetes T2 cases. It is also estimated 
that over the next years poorer countries suffer a  steady increase in the number of patients as 
the economy will develop and socioeconomic changes happen, leading to a rise in bad eating 
habits, (World Health Organization, 2016.b).  
2.2. Traditional Treatment and Timeline  
Wu (2019) states that the first dated discoveries about diabetes were in the 20th century, when 
patients would die in weeks or months after the first symptoms. Fortunately, in the current 
context there are many treatment options available. The table below depicts the timeline from 
the main discoveries to current days.  
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1915 1922 1955 
"Starvation dieting", lack of 
calories and carbohydrates 
was used to treat diabetes at 
that time until the 
commercialization of insulin 
Leonard Tompson, first patient 
to be treated with insulin from 
pigs 
First oral pills 
commercialized for 
diabetes type 2 patients 
1961 1964 1968 
Commercialization of 
Glucagon, hormone to treat 
hypoglycemia  
Introduction of test strips to 
check blood glucose  
Use of the HbA1c test to 
monitor the efficiency of 
treatments  
1976 1982 1999 
Development of the first 
wearable insulin pump to a 
limited number of patients 
Creation of the human insulin  
First continuous glucose 
monitoring (CGM) and 
insulin pump approved to 
limited number of patients  
2000 2014 2016 
Introduction of the long-acting 
insulin, Lantus  
Approval of the flash-glucose 
and CGM sensors for 
commercial use in Europe 
The first artificial pancreas 
was approved for 
commercial use  
Table 1 – Diabetes treatment timeline 
Source: Own elaboration based on American Diabetes Association (2020.b), Wu (2019) and 
Gebel (2012) 
 
2.3. Innovation and Technology   
As shown in table 1, there are many changes in diabetes treatment over the years and technology 
is responsible for a major part of it. Technologies started to be developed in 1976, but only in 
recent years patients were actually able to buy it, (American Diabetes Association, 2020.b). 
Nowadays, there are several options of devices and monitors that can be used to treat the 
disease, from flash glucose monitoring, insulin pumps, artificial pancreas to smartphone 
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applications. For further analysis purposes, the table below depicts the main technologies 
available in the market and their definitions.  
Technology Definition  
Self-monitoring of blood 
glucose (SMBG) or blood 
glucose test strips 
Strips that collect patient's blood from a finger test giving 
the glucose level. The newest models come with 
smartphone applications connection  
Smart insulin pens  
Insulin pens that have a variable options of doses, being 
able to adapt to patient's treatment. Some of them come 
with a smartphone application to support the calculation of 
necessary units  
Flash Glucose Monitoring 
(FGM)  
Sensor attached to the patient's body that when scanned 
shows the blood glucose level  
Continuous Glucose Monitoring 
(CGM)  
Sensor that regularly checks patient’s glucose and sends to 
a monitor by WIFI or Bluetooth  
Insulin pumps or Continuous 
subcutaneous insulin infusion 
(CSII) 
Device that automatically injects insulin in the patient's 
body with commands  
Artificial pancreas 
A CGM sensor to check glucose levels and a pump to 
inject insulin according to the data from the sensor. It is 
the most advanced technology in the market, called closed 
loop system  
Table 2 – Diabetes technologies and definition 
Source: Own elaboration based on Roche (2020), Ahn (2019), Abbott (2020), Medtronic 
(2019), Sora (2019) and Wetsman (2019) 
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2.3.1. Impact   
Although technology official use is new in the market, it has already started to show impacts in 
different areas, especially in financial aspects and treatment results. According to an article 
from Abbott, the FreeStyle Libre FGM sensor has diminished the number of times a patient 
needs to visit doctors and hospitals, consequently lowering overall costs, (Abbott, 2019.b). As 
for smartphone applications, Whaley et al. (2019) states that patients using traditional blood 
glucose measurement combined with smartphone applications reduced their medical costs in 
21,9%.  
Regarding treatment results, as stated by Beck et al. (2017) the American Diabetes Association 
conducted a trial to measure the impact of FGM and CGM in patients’ treatments in the United 
States. It was observed that patients lowered the number of extreme events in around 31% and 
increased in 44% good blood glucose levels.  
2.4. Accessibility  
Having described the traditional and advanced treatments existents, it is important to know that 
many patients are not able to access these supplies. The International Diabetes Federation 
(2019) estimates that approximately one in two people with diabetes T2 have access to the right 
treatment prescribed by the doctor. This number changes depending on the region, in African 
countries for example, it is known that only 24% of the patients have access to insulin in contrast 
with 90% in high income countries. As stated by the World Health Organization (2016.b), the 
contrast between regions is preoccupying as the majority of patients live in middle to low 
income regions and it is known that these are the countries with the highest estimated growth 
for the next years.  
Furthermore, not only the economic reality of the country affects accessibility of the treatment. 
Novo Nordisk (2020), the biggest insulin producer in the world, states that there are other 
factors, such as the healthcare system of each country, education on diabetes and supply chain 
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that impact on the adoption of basic treatment worldwide. When it comes to technology 
treatment, Naranjo et al. (2016) says that the most relevant barriers are psychological, structural 
and demographic, composed by financial and economic context, education on diabetes and 
technology, insurance systems, regulatory guidelines and the possible errors from technology 
functioning. As an example to understand more about the adoption curve of technologies, the 




Figure 1 – Dissemination of technologies in the United States per percentage of patients 
Source: Retrieved from Frederick et al. (2016) 
Basic technologies such self-monitoring blood glucose (SMBG) is widely available in the 
United States, as 99% of T1 and 89% of T2 patients make use of it in their treatment. However, 
advanced technologies such as continuous glucose monitoring (CGM) and insulin pumps (CSII) 
still need improvement in accessibility, (Frederick et al., 2016). In 2017 it was estimated that 
only 15% of total T1 diabetic patients in the United States make use of a CGM device (Close, 
2017), a slight increase in comparison with the information from figure 1.  
Moreover, the FGM system was not available during the period described in the picture,  but it 
is known that there are between 1.5 million to 2 million users of the FreeStyle Libre sensor 
since its beginning in 2014. It is important to highlight that there are more than 460 million 
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patients around the world, meaning that there is a small slice of them using FGM sensors, 
(Abbott 2019.a).  
According to the information presented above, this work project aims to address and explore 
four factors that impact technology accessibility around the world. The next sections will be 
dedicated to understand this topic in dept.   
3. Methodology 
Based on the objective of this paper, a qualitative research was the methodology chosen to 
develop it. The work project is composed by a contextualization of the scenario and further 
analysis of already existing documents, based on findings and exploration rather than testing 
hypothesis. 
The elements of the paper were categorized and interpreted according to data from healthcare 
and political institutions, companies reports, previous papers and websites. All the documents 
used were chosen according to its reliability and quality of the information provided, institutions 
such as the United Nations and World Health Organization to papers from specialists on the 
diabetes and technology topics, were used as sources.   
The information found on the sources were analyzed and put in the context of this research, so 
they could be interpreted by the author. The learnings retrieved from the sources were combined 
with other findings, therefore, the author was able to create her own opinion about the topic.  
A quantitative method was not suitable for this research as the objective was not to measure or 
create patterns based on data. Additionally, as previously described, because the use of 
developed technology in diabetes care is relatively new, there are not enough quantitative data 
that could support the question to be analyzed. Accordingly, because of the limitations in the 
quantitative approach for this context and the objective of the research, the author chose to use 
a qualitative methodology.          
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4. Analysis  
4.1.Measuring the future impact  
Considering the positive outcomes from technology development described in this paper, it is 
possible to see that innovation is already making a great advance in different areas of diabetes 
care. However, these results are part of a small slice of patients that have access to technologies, 
as described previously.  
What specialists know is that diabetes technologies are indeed seeing a rise in its adoption 
worldwide – considering the market size (exhibit 3) – and there is an effort in the community 
to evaluate the real impact of technology in diabetes care in the future. However, it is necessary 
a much larger amount of data to estimate concrete results, especially considering that the 
majority of patients adopting technologies come from high-income countries – as it will be 
shown in the topics below – leading to a lack of results from a  different socioeconomic reality.        
Accordingly, now it is important to understand the factors that influence the adoption of 
technological devices around the world, thus, it is possible to better estimate concrete results 
and take actions in the future when the necessary quantitative information  become available.  
This being said, the factors analyzed were chosen according to the literature studied to conduct 
this research and the author’s understanding of relevance, knowing that they are not the only 
ones impacting technology adoption.  
4.1.1. Education on diabetes and technology 
Many people around the world are not aware of their diabetes diagnosis, along with that, it is 
estimated that only 50% of T2 patients have the right treatment, meaning that a small percentage 
of diabetics are actually educated about their condition. According to the Brazilian Diabetes 
Association (Sociedade Brasileira de Diabetes, 2019), diabetes education is one of the main 
pillars of self-management, especially for patients using new technologies. The Juvenile 
Diabetes Research Foundation (2020), also states that having the right information about the 
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disease is a decisive factor for technology adoption and positive treatment results in the United 
Kingdom.  
Additionally, both reports state that patients rely on information from doctors and nurses, thus, 
if these professionals do not have enough time and are not educated to provide information 
about new technologies, it is unlikely that patients will adopt the use of devices by themselves. 
In the United Kingdom, users of such devices also state that the reason that affect the most their 
choice to look for a different treatment was their doctors’ opinion, in 42% of the cases, 
confirming again that patients rely on health experts to take a big part of the decision, even 
though there is easy information about technological treatments online.  
Furthermore, according to Heerden et al. (2017), devices require a middle and high level of 
education on technology and how to handle possible outcomes from the adoption. Along with 
that, the American Diabetes Association (2020.a) states that the constant changes and 
development in diabetes technology might create a complex context if the patient has a low 
level of technology acquaintance. Schneider (2019) also says that regardless of the 
socioeconomic situation and the possible coverage by the public healthcare system or private 
insurance, the patient needs to be eligible to wear the technology, meaning that it is necessary 
a basic technical training on how to handle it before the adoption.  
As approximately half of the world have access to internet connection, it is unlikely that the 
other offline 50% have enough technology access and knowledge to deal with advanced devices 
and applications, (Roser et al., 2020).   
Moreover, considering that 90% of diabetes cases in the world are T2, composed by adults or 
older patients, it is harder for them to adopt in their daily lives such advanced technology and 
especially keep up with different devices and smartphone applications rapid changes. Also, 
because devices give patients so much more freedom, it is easier to make a mistake without 
doctors advices, thus, not every patient can use it, (Herden et al., 2017).   
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Diabetes and technology education are influenced by many factors, prepared professionals to 
teach about the advanced treatment, active learning from patients, understanding of their own 
personal limitations, access to internet and acquaintance with basic technologies such as 
smartphones. All of these elements indirectly impact the adoption of technology treatment in 
the educational context, (Sociedade Brasileira de Diabetes, 2019).  
All in all, taking in consideration that there is a high percentage of patients who are not aware 
of their condition or do not properly have access to care, summed with the context of lack in 
technological knowledge, there is a long way to provide the necessary education to a higher 
adoption of devices and smartphones applications.    
4.1.2. Regulatory agencies  
Diabetes technologies are being developed for many years, taking in consideration the table 1 
of this paper, it is noticeable that the advanced supplies currently commercialized had its first 
versions years ago, such as the insulin pump in 1976, limited to clinical trials and patients tests. 
Regulatory agencies have an important role in this process, institutions such as the Food and 
Drug Administration (FDA) from the United States, are responsible for the approval of all new 
treatments, and that can take from three to seven years in average when considering devices 
that require high human interaction, (Norman, 2016). As every country has its own regulatory 
agency, the time needed to put medical technologies in the market can vary from region to 
region. Take FreeStyle Libre from Abbott as an example, the FDA approved in 2016 its use for 
clinical trials, it took one year after that to approve it for patients use, but in Europe the device 
was already available since 2014, (Blum, 2018). 
Not only countries have a different timeline in terms of development to approval, but also the 
type of product has variations and different regulations needed. According to Fleming et al. 
(2019), smartphone applications created to support diabetic patients in the United States and in 
European countries are unregulated in your majority, mostly because of a lack of evidence on 
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security and data. There is a concern from the authorities to regulate such applications without 
concrete data and conclusive tests because of such important decisions taken with the 
information provided by them.   
Furthermore, the considerable recent rise of the cybersecurity topic, has put authorities in a 
dead-lock between keeping patient’s data safe and not interfere in its collection from the 
healthcare institutions for development purposes. Regulatory agencies have based diabetes 
technology security in other medical devices, and it has been a barrier for faster advances and 
adoption because of many threats from the past, such as groups trying to hack cardiac 
pacemakers, (Ginsberg; Klonoff; Crabtree, 2017). 
CGM, FGM and CSII have shown to be susceptible to invasion years ago, there are several 
cases of patients hacking into the devices to develop new functions or to collect private data. 
Even before an official commercialization of CGM or artificial pancreas systems, there were 
already patients using non regulated smartphone applications to hack basic technologies and 
turn them into what became available in the market years after, (Ginsberg; Klonoff; Crabtree, 
2017).   
Therefore, regulatory agencies tend to create guidelines that limit users of such technologies. 
As previously discussed, patients must have a high level of diabetes and technical education to 
become an user, not only the device itself requires this knowledge during daily life, but also 
federal agencies recommend healthcare institutions, governments and insurance agencies to 
limit users because of this fact, (Ginsberg; Klonoff; Crabtree, 2017). 
Considering this, regulatory agencies have an important role in technology adoption as at the 
same time they need to be aware of possible negative outcomes in terms of security, an extreme 
limitation of these technologies may hold development and commercialization to patients.    
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4.2.3. Socioeconomic reality   
The cost of purchasing technological devices is one of the most common barriers for patient’s 
adoption around the world, mainly those with higher income compose the majority of people 
able to afford these options, as the ones coming from a lower income reality need to rely on the 
healthcare system or donations, (International Diabetes Federation, 2019).   
High income countries are the ones with the highest expenditure in diabetes care adjusted per 
patient, meaning that governments and healthcare institutions have a larger budget to spend in 
the particular disease. The figures below depict the ranking of the ten countries with the lowest 
and highest expenditure per adult patient in 2019.  
 
 
Figure 2 – Countries with the lowest expenditure per patient in 2019 
Source: Own elaboration based on the World Health Organization (2016.a) 
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Figure 3 – Countries with the highest expenditure per patient in 2019 
Source: Own elaboration based on the World Health Organization (2016.a) 
Using the information from figure 3, Switzerland is the country with the highest expenditure 
per diabetic patient. Also, according to the World Health Organization (2016.a), the country 
has 5.6% of the population with diabetes, most of the basic technologies are available in the 
public health system and advanced technologies can be acquired by a private insurance or can 
be reimbursed by the government depending on the context – this last factor will be addressed 
in the next topic.  
However, Bangladesh has 8% of its population with diabetes, provides only two out of seven 
basic technologies to patients in the primary care and according to figure 2, is the country that 
spends the least in patient’s treatment. Going further, India, which is the second country in 
number of patients, also lacks in governmental investment in patient’s care and has only two 
out of seven basic technologies available, (World Health Organization, 2016.a).  
What it is interesting to notice is that the percentage of diabetic patients in the country is not a 
determinant factor for a higher adoption of devices, the socioeconomic reality indeed has a 
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stronger impact in this context. As showed, developed countries with a lower percentage of 
patients – with the exception of the United states – have a higher adoption of technologies.  
Furthermore, according to data from Abbott’s FGM sensor, FreeStyle Libre, 59% of the total 
devices around the world come from five high income countries: United States, Italy, Germany, 
Japan and France, (Calliari et al. 2019).  
Having in mind the five countries with the highest incidence of diabetes – China, India, United 
States, Pakistan and Brazil – it  would be proportionally logical if the highest adoption of 
technologies included these countries. However, we have seen that it is not the case, with the 
exception of the United States.   
Additionally, according to the World Health Organization (2016.b) report, low-income 
countries usually charge more from patients when it comes to buying more advanced tools, such 
as smart insulins pens. Governments from such countries, choose the “wrong” suppliers and as 
a consequence, it leads to a higher mark-up in the final price. For a better understanding of the 
world picture on smart insulin prices, see exhibit 4.   
The International Diabetes Federation report (2019) on accessibility around the world, 
described that only 10% of patients in low-income countries make use of smart insulin pens in 
comparison with 75% in high-income regions. Although poorer countries do have different 
recommendations to provide access of basic and technological treatments to the population, it 
does not seem to work as expected, many governments report difficulty to reach an affordable 
supplier or even to be able to negotiate with companies that develop devices for a cheaper price. 
Moreover, the economic factor is not only impacted by the country’s income category, but also 
on the patient’s financial reality. Bennett and Hazelton (2019) conducted a study in the United 
Kingdom with the objective to address important information about accessibility of devices in 
the region. They affirm in the Juvenile Diabetes Research Foundation report that approximately 
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12% of the high-income respondents in the United Kingdom were unaware of the flash-glucose 
devices, but the percentage doubles to 24% when analyzed patients with a lower income.    
Regarding South African patients, according to Petersen (2018), the context is worse in poorer 
countries as smartphone applications and many devices require internet connection or phone 
data and many patients cannot afford to pay for it.  
To conclude this topic, it was showed that the socioeconomic factor has a high impact in 
accessibility. It is also essential to understand that patients from a high income country do not 
always live in this condition, thus, his personal financial context also affects weather he is able 
to acquire technologies or not.  
4.1.4. Public healthcare and insurance coverage  
When healthcare systems or private insurances cover part of a diabetic patient treatment, most 
of the times it includes only traditional supplies, making the financial cost of the disease go up 
as diabetes requires a high investment and many patients cannot afford paying for the treatment 
privately, (World Health Organization report 2016.b).  
Messer and Weinzimer (2020) state that the traditional glucose level tests (SMBG) are in major 
covered by health insurances in most European countries and, as described in figure 1, it is 
widely available in the United States, being the opposite reality in other continents. As 
regarding CGM and CSII, these devices are not covered in many cases and in the United States 
it is estimated that three quarters of all patients already using an insulin pump cannot renew the 
reimbursement.  
According to Graham (2017), a decisive factor that impacts the coverage of CGM is the health 
state of the patient. Similarly, the majority of cases in which CSII are covered belong to patients 
that need to use the device for treatment purposes, meaning that those who want to use but 
maintain a good control of the disease with traditional supplies, will have a harder time to get a 
coverage for a technological option.  
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On the other hand, FGM devices are already included in some insurances policies in high-
income countries. Technology development seem to be pushing insurance agencies and 
countries to change their policies, as many health specialists advise the use of a more 
technological option, there are already countries preferring to reimburse FGM devices instead 
of traditional glucose strips (SMBG), encouraging patients to adhere to the first one. It is also 
important to state that FGM systems are cheaper and easier to manipulate than CSII and CGM 
devices, thus it is expected that it is more accessible, (Graham, 2017).  
For a better overview of diabetes technology coverage, table 3 depicts the number of basic 
technologies available for free in the public care system in low to middle income countries. It 
is followed by table 4 that describes the guideline for reimbursement or coverage of CSII and 
CGM devices in the public care in high income countries.   
 
Country 
Availability in public care 







Table 3 – Basic technologies available in public care 





Country Coverage or reimbursement 
United States 
Coverage for CGM and pumps in 
T1 patients only 
United Kingdom 
Coverage for pumps and CGM on 
cases that the patient has an 
unstable control of the condition 
Switzerland 
Coverage for CGM and pumps on 
cases that the patient has an 
unstable control of the condition 
Austria 
Coverage of pumps and CGM on 
cases that the patient has an 
unstable control and pregnant 
women 
Norway 
Coverage for CGM and pumps 
depending on local budget 
Table 4 – Advanced technologies coverage 
Source: Own elaboration based on Graham (2017) and Iotova et. al (2017) 
It is noticeable that countries in table 3 are not able to provide basic technologies to patients, 
such as insulin pens, blood tests and SMBG. Pakistan, the fourth country in number of patients 
worldwide, does not provide any technology in public care. Also, crossing with the information 
provided in the figure 2, there is a correlation between countries that have the lowest investment 
per patient and those that cannot provide basic or advanced technologies – as we have seen 
these are the regions with highest percentage of diabetics.  
On the other hand, looking at table 4, the countries described there not only provide basic 
technologies but also cover or reimburse the advanced ones such as CSII and CGM. Important 
to mention that even high income countries do have limits in terms of coverage, as mentioned 




5.1. Discussion  
It was indeed concluded that the four factors explored impact technology adoption by diabetic 
patients around the world. Education on diabetes and technology showed to be very important 
as a basic step to accessibility, it was learned that a misinformation on the treatment leads to 
unawareness of devices existence and its functions, relying on healthcare experts to receive 
information. As for lack of technology handiness, because guidelines require this as basic 
knowledge, it limits patients on eligibility to be an user of such innovations.  
Additionally, the socioeconomic context creates a barrier on the adoption financially speaking, 
knowing that 80% of the patients live in middle to low income regions and technologies require 
high financial investment, many of them cannot afford to acquire devices or even basic supplies 
as internet connection – necessary to the usage – thus, the majority of adopters come from high 
income countries. Moreover, the public healthcare system, that could be a partial solution for 
the socioeconomic issue, either do not cover basic technologies in public care in poor countries 
or limit patients per health condition in developed ones, which leads to again rely on personal 
financial condition in many cases. 
As for an external factor, it was learned that regulatory agencies play an important role in 
approving technologies to be commercialized. It was discussed that countries have a different 
guideline for devices and smartphone applications approval, delaying the adoption in some 
regions in comparison with others.   
In the author’s opinion, all the factors analyzed should work together to promote  technologies 
accessibility, logically the factors are also connected, the socioeconomic context is a barrier 
itself to education on diabetes and technology. Similarly happens to public healthcare system, 
if the country does not have enough financial funding, hardly it will invest in technologies 
before basic care.  
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The work project obtained its objective to analyze and explore the four factors and present how 
they impact accessibility among patients. The information provided is important to understand 
the diabetes challenge and which points are necessary to be addressed to increase adoption 
around the world, providing better life quality and economic relief to patients and governmental 
institutions. 
5.2. Limitations  
Concerning the limitations found during the development of this research, the author found it 
challenging to reach documents about technology adoption in some regions of the world, such 
as Central America and South East Asia. The information found in institutions such as United 
Nations, International Diabetes Federation or World Health Organization give an overview 
about technology adoption in non-developed countries, however, there are no conclusive 
numbers.   
Regarding the types of technologies discussed in the research, depending on the level of 
development, some devices or applications have more available information than others, 
leading to a paper focused mainly on five technologies – smart insulin, flash glucose sensors, 
continuous glucose monitoring systems, insulin pumps and smartphone applications – it is 
important to say that there are many technologies in the market besides the ones addressed in 
the research, such as inhaled insulin, artificial pancreas and other systems.  
Finally, the factors analyzed as barriers for technology adoption around the world were chosen 
according to the author’s understanding of importance and value for the analysis based on 
previous research of the bibliography. There are other factors that could have been analyzed, 
but because of space and information relevance the author had to restrict to the ones addressed.  
5.3. Further work 
As a next step, it would be interesting to conduct a quantitative work project based on the 
qualitative information provided here. The focus would be on creating a model to understand 
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what is the proportion of the impact from the four factors in technology adoption. The next 
research would provide a deeper understanding of where governments and healthcare 
institutions could focus to improve accessibility around the world and also which factor is more 
important depending on the region addressed. 
To conclude, in the next years the diabetes community will have a larger amount of data 
available from technologies, also better categorized from country to country, being a start to 
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Exhibit 1 – Diabetes prevalence around the world in percentage of the population 
 
 










Exhibit 2 – Number of diabetic patients in 2019 
 
Source: Own elaboration based on World Health Organization (2016.a) 
 
Exhibit 3 – Size of the CGM market in the world 
Year Size of the market (billions of USD)  
2017 USD 11,98 
2018 USD 12,63 
2019 USD 13,33 
2020 USD 14,09 
2021 USD 14,92 
2022 USD 15,83 
2023 USD 16,83 
2024 USD 17,91 
2025 USD 19,11 
2026 USD 20,42 
2027 USD 21,85 








Country Number of patients in 2019 (in millions)  
China  116,4 
India 77 







Bangladesh  8,4 
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Exhibit 4 – Price of smart insulin pens according to income (USD)  
 
Source: Retrieved from World Health Organization (2016.b) 
